Anticipated $-0.56 EPS for Trillium Therapeutics Inc. (TRIL) on May, 11

April 17, 2018 - By Patrick Harkless

On May, 11 WallStreet expected Trillium Therapeutics Inc. (NASDAQ:TRIL)’s earnings release, Zacks reports. This year’s earnings per share analyst estimate is expected to be $-0.56. That is 49.09 % up compareed to $-1.1 earnings per share for last year. Analysts at Wall Street see Trillium Therapeutics Inc.’s -22.22 % EPS growth compared to $-0.72 earnings per share for last quarter. Its shares touched $6.9 on during the last trading session after 2.13% change.Trillium Therapeutics Inc. has volume of 44,560 shares. Since April 17, 2017 TRIL has risen 12.70% and is uptrending. TRIL outperformed the S&P 500 by 1.15%.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Coverage

Total analysts of 2 have positions in Trillium Therapeutics (NASDAQ:TRIL) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since December 14, 2017 according to StockzIntelligence Inc Trillium Therapeutics has 3 analyst reports. On Friday, April 13 the stock has “Hold” rating by Leerink Swann. In Thursday, December 14 report H.C. Wainwright maintained the stock with “Buy” rating. On Monday, March 12 the stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) earned “Buy” rating by H.C. Wainwright.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer.The company has $86.03 million market cap. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.Last it reported negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: